Wedbush Lifts Apogee Therapeutics (APGE) Price Target to $135, Reiterates Outperform

Wedbush Securities on May 28, 2026, reaffirmed its Outperform rating on Apogee Therapeutics Inc. (NASDAQ: APGE) and raised its 12-month price target to $135. The upward revision signals growing confidence in the clinical-stage biotech’s pipeline progress. The new target implies considerable upside from the stock’s recent trading range, though the prior target was not disclosed. Wedbush’s analyst cited upcoming catalysts expected to drive value, without providing further specifics. Apogee’s shares have drawn increased attention as the company advances its therapeutic candidates through development.